Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Immune checkpoint inhibitors (ICIs) show real anti-tumor activity in solid organ transplant recipients with cutaneous malignancies, but nearly 1 in 4 patients lost their transplanted organ. Meanwhile, alternatives like T-VEC and hedgehog pathway inhibitors delivered strong responses with zero reported graft rejections — making them worth a closer look for this high-risk population.
Immune checkpoint inhibitors (ICIs) can effectively treat skin cancers in solid organ transplant recipients (SOTRs), but they come with a serious trade-off: a high risk of the body rejecting the transplanted organ. A systematic review published in Dermatologic Surgery analyzed 196 transplant patients treated for cutaneous malignancies — including squamous cell carcinoma, melanoma, and Merkel cell carcinoma — and found that while ICIs produced meaningful tumor responses, graft outcomes were concerning.
On the brighter side, two alternative therapies — talimogene laherparepvec (T-VEC) and sonic hedgehog pathway inhibitors (HPIs) — showed high response rates with no reported graft rejections or failures, suggesting they may be safer options for this vulnerable population.
By the Numbers
Why it matters: Transplant recipients are at significantly elevated risk for skin cancers due to long-term immunosuppression, yet treating those cancers with ICIs can trigger the immune system to attack the transplanted organ. Finding safer, effective alternatives is critical — and T-VEC and HPIs look promising, though larger studies are urgently needed.
